Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Gains from Investment Securities (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Gains from Investment Securities for 5 consecutive years, with $69000.0 as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Gains from Investment Securities fell 46.86% year-over-year to $69000.0, compared with a TTM value of $109120.0 through Mar 2019, down 93.5%, and an annual FY2024 reading of -$63000.0, down 107.97% over the prior year.
  • Gains from Investment Securities was $69000.0 for Q3 2019 at Larimar Therapeutics, down from $109120.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $5.0 million in Q4 2018 and bottomed at $13273.0 in Q4 2016.
  • Average Gains from Investment Securities over 5 years is $1.3 million, with a median of $1.2 million recorded in 2015.
  • The sharpest move saw Gains from Investment Securities tumbled 98.66% in 2016, then soared 4043.75% in 2017.
  • Year by year, Gains from Investment Securities stood at $992505.0 in 2015, then crashed by 98.66% to $13273.0 in 2016, then skyrocketed by 4043.75% to $550000.0 in 2017, then soared by 813.52% to $5.0 million in 2018, then crashed by 98.63% to $69000.0 in 2019.
  • Business Quant data shows Gains from Investment Securities for LRMR at $69000.0 in Q3 2019, $109120.0 in Q1 2019, and $5.0 million in Q4 2018.